GENETIC MARKERS INDICATIVE OF A CANCER PATIENT RESPONSE TO TRASTUZUMAB (HERCEPTIN)

摘要

The invention relates to the fields of therapeutics and identifying candidates for therapy, in particular to a method of identifying candidates for trastuzumab (Herceptin®) therapy in a patient presenting with breast cancer based on the presence or absence of specific genetic markers in a tumor sample from said patient.

主权项

1. A process of producing information indicative of whether a human cell has a deletion at human chromosome region Chr18:309355-76106388 (marker D3), a deletion at human chromosome region Chr15:20444124-88087873 (marker D11), a deletion at human chromosome region Chr8:2780282-31010773 (marker D26), a deletion at human chromosome region Chr17:1612008-46199917 (marker D31), a deletion at human chromosome region Chr18:44824169-76106388 (marker D57), a deletion at human chromosome region Chr17:36157799-41605371 (marker D58), an amplification at human chromosome region Chr11:5755441-5766622 (marker A1), an amplification at human chromosome region Chr11:5755441-5756473 (marker A73) or an amplification at human chromosome region 5q169.81-q185.239 (marker B), comprising determining by apparatus a copy number for marker D3, marker D11, marker D26, marker D31, marker D57, marker D58, marker A1, marker A73, or marker B, thereby producing information indicative of whether the human cell has a deletion at marker D3, a deletion at marker D11, a deletion at marker D26, a deletion at marker D31, a deletion at marker D57, a deletion at marker D58, an amplification at marker A1, an amplification at marker A73, or an amplification at marker B.